LNSR supply chain intelligence for LENSAR, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
LENSAR, Inc. (LNSR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| WELLS-FARGO-BANK-N-A | WELLS-FARGO-BANK-N-A | 92% | The PCL Agreement provides for a revolving, non-purpose margin credit facility, secured by a first-priority lien on a designated brokerage account maintained at Wells Fargo |
| SUPPLIERS | SUPPLIERS | 85% | We purchase custom and off-the-shelf components from a number of suppliers, including some single-source suppliers. |
| CHINA | CHINA | 80% | we sell our products through distributor relationships |
| GERMANY | GERMANY | 80% | we sell our products through distributor relationships |
| SOUTH-KOREA | SOUTH-KOREA | 80% | we sell our products through distributor relationships |
| BHC | Bausch Health Companies Inc. | 72% | zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently is cleared for marketing in the United St… |
| BHC | Bausch Health Companies Inc. | 72% | Reciprocal relationship from BHC graph: Reciprocal relationship from LNSR graph: zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and… |
| BLCO | Bausch + Lomb Corporation | 72% | Reciprocal relationship from BLCO graph: Reciprocal relationship from LNSR graph: Reciprocal relationship from BLCO graph: Reciprocal relationship from LNSR graph: Reciprocal relationship from BLCO g… |
| JNJ | Johnson & Johnson | 72% | zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently is cleared for marketing in the United St… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from LNSR graph: zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ASCS | ASCS | 90% | we and our distributors typically market and sell our systems to ASCs, hospitals and physicians |
| HOSPITALS | HOSPITALS | 90% | we and our distributors typically market and sell our systems to ASCs, hospitals and physicians |
| PHYSICIANS | PHYSICIANS | 90% | we and our distributors typically market and sell our systems to ASCs, hospitals and physicians |
| PDL-BIOPHARMA-INC | PDL-BIOPHARMA-INC | 85% | 185 Total 2,756 2,872 Less accumulated depreciation ( 2,385 ) ( 2,381 ) Construction in progress 293 188 Property and equipment, net $ 664 $ 679 Depreciation expense on property and equipment amounte… |
| BHC | Bausch Health Companies Inc. | 72% | zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently is cleared for marketing in the United St… |
| BHC | Bausch Health Companies Inc. | 72% | Reciprocal relationship from BHC graph: Reciprocal relationship from LNSR graph: Reciprocal relationship from BHC graph: Reciprocal relationship from LNSR graph: zation efforts will provide us with s… |
| BLCO | Bausch + Lomb Corporation | 72% | Reciprocal relationship from BLCO graph: Reciprocal relationship from LNSR graph: antee that the Company will be able to meet customer demand for the ALLY System. In addition, pricing increases in co… |
| BLCO | Bausch + Lomb Corporation | 72% | antee that the Company will be able to meet customer demand for the ALLY System. In addition, pricing increases in component parts for our Systems resulting from inflationary pressures and other macr… |
| JNJ | Johnson & Johnson | 72% | zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently is cleared for marketing in the United St… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from LNSR graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from LNSR graph: Reciprocal relationship from JNJ grap… |
| ALCON-RESEARCH-LLC | ALCON-RESEARCH-LLC | 62% | ng of these clearances or certifications, among other factors. Our future revenue and cash flows will depend on, among other factors, our installed base of Systems and the timing of and applicable cl… |
| ARTIFICIAL-INTELLIGENCE-TECHNOLOGIES | ARTIFICIAL-INTELLIGENCE-TECHNOLOGIES | 62% | res are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate technologies or features that are important or … |
| CARL-ZEISS-AG | CARL-ZEISS-AG | 62% | antee that the Company will be able to meet customer demand for the ALLY System. In addition, pricing increases in component parts for our Systems resulting from inflationary pressures and other macr… |
| NR-GRI-PARTNERS | NR-GRI-PARTNERS | 62% | cluding common stock, preferred stock, warrants, and/or debt securities through private placement transactions or registered public offerings in the future. If we issue equity securities to raise add… |
| VMI-OPTION-MERGER-SUB-INC | VMI-OPTION-MERGER-SUB-INC | 62% | ng of these clearances or certifications, among other factors. Our future revenue and cash flows will depend on, among other factors, our installed base of Systems and the timing of and applicable cl… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LNSR-DEBT-10744 | Warrants outstanding: 10338000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| LNSR-DEBT | Debt stack $2.6M | 90% | Market cache reports total debt of $2.6M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LNSR-OWNER-BRANDES-INVESTMENT-PARTNERS-LP | BRANDES INVESTMENT PARTNERS, LP | 90% | 13F overlay lists BRANDES INVESTMENT PARTNERS, LP as top holder; 88 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ABBV | AbbVie Inc. | 100.00 | 2 | |
| AURA | Aura Biosciences, Inc. | 100.00 | 2 | |
| CLGN | CollPlant Biotechnologies Ltd. | 100.00 | 2 | |
| ADGM | Adagio Medical Holdings, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| ACIU | AC Immune SA | 100.00 | 2 | |
| BHC | Bausch Health Companies Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| BLCO | Bausch + Lomb Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| ALC | Alcon Inc. | 100.00 | 2 | |
| ATON | AlphaTON Capital Corp | 100.00 | 2 |